Refractory immune thrombocytopenic purpura: Current strategies for investigation and management Review uri icon

Overview

MeSH Major

  • Purpura, Thrombocytopenic

abstract

  • There is currently no consensus on how best to manage refractory immune thrombocytopenic purpura (ITP). In part, this reflects the need for individualized treatment due to the wide spectrum of patients' requirements and responsiveness to therapies. The objective of this review is to provide a clinically useful guide to current management strategies. This article suggests investigations to identify factors that may exacerbate thrombocytopenia and underlie poor therapeutic responses, and highlights emerging therapies, including the thrombopoietic agents, which are anticipated to dramatically alter the natural history of "refractory" ITP. Morbidity, mortality and heath-related quality of life are also discussed.

publication date

  • October 2008

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1111/j.1365-2141.2008.07275.x

PubMed ID

  • 18573111

Additional Document Info

start page

  • 16

end page

  • 26

volume

  • 143

number

  • 1